587 related articles for article (PubMed ID: 26740249)
21. Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.
Richardson E; Ryan KA; Lawrence RM; Harle CA; Young A; Livingston MD; Rawal A; Staras SAS
J Community Health; 2021 Aug; 46(4):808-816. PubMed ID: 33389475
[TBL] [Abstract][Full Text] [Related]
22. Individual Preferences for Child and Adolescent Vaccine Attributes: A Systematic Review of the Stated Preference Literature.
Michaels-Igbokwe C; MacDonald S; Currie GR
Patient; 2017 Dec; 10(6):687-700. PubMed ID: 28474295
[TBL] [Abstract][Full Text] [Related]
23. Meningococcal disease and vaccination: Knowledge and acceptability among adolescents in Italy.
Pelullo CP; Napolitano F; Di Giuseppe G
Hum Vaccin Immunother; 2018 May; 14(5):1197-1202. PubMed ID: 29452028
[TBL] [Abstract][Full Text] [Related]
24. Parental and societal values for the risks and benefits of childhood combination vaccines.
Gidengil C; Lieu TA; Payne K; Rusinak D; Messonnier M; Prosser LA
Vaccine; 2012 May; 30(23):3445-52. PubMed ID: 22449423
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
26. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
[TBL] [Abstract][Full Text] [Related]
27. Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.
Mameli C; Faccini M; Mazzali C; Picca M; Colella G; Duca PG; Zuccotti GV
Hum Vaccin Immunother; 2014; 10(10):3004-10. PubMed ID: 25483638
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
[TBL] [Abstract][Full Text] [Related]
29. Using discrete choice modeling to evaluate the preferences and willingness to pay for leptospirosis vaccine.
Arbiol J; Yabe M; Nomura H; Borja M; Gloriani N; Yoshida S
Hum Vaccin Immunother; 2015; 11(4):1046-56. PubMed ID: 25764105
[TBL] [Abstract][Full Text] [Related]
30. Control of invasive meningococcal disease: is it achievable?
Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
[TBL] [Abstract][Full Text] [Related]
31. Meningococcal B vaccination coverage among older adolescents in the United States.
La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P
Vaccine; 2021 May; 39(19):2660-2667. PubMed ID: 33849722
[TBL] [Abstract][Full Text] [Related]
32. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.
MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381
[TBL] [Abstract][Full Text] [Related]
33. Public preference for COVID-19 vaccines in China: A discrete choice experiment.
Dong D; Xu RH; Wong EL; Hung CT; Feng D; Feng Z; Yeoh EK; Wong SY
Health Expect; 2020 Dec; 23(6):1543-1578. PubMed ID: 33022806
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
[TBL] [Abstract][Full Text] [Related]
35. Awareness is not enough: the need to increase meningococcal vaccine uptake.
Coyne-Beasley T; Reiter PL; Liberty AC; Ford CA; Miles DR; Brewer NT
Clin Pediatr (Phila); 2013 May; 52(5):441-50. PubMed ID: 23539687
[TBL] [Abstract][Full Text] [Related]
36. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
Moura Silveira M; McBride AJA; Trotter CL
Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
[TBL] [Abstract][Full Text] [Related]
37. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
Tirani M; Meregaglia M; Melegaro A
PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
[TBL] [Abstract][Full Text] [Related]
38. Parental Preferences of Influenza Vaccination for Children in China: A National Survey with a Discrete Choice Experiment.
Jiang M; Gong Y; Fang Y; Yao X; Feng L; Zhu S; Peng J; Shi X
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206343
[TBL] [Abstract][Full Text] [Related]
39. Can we control all-cause meningococcal disease in Europe?
Sadarangani M; Pollard AJ
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
[TBL] [Abstract][Full Text] [Related]
40. Vaccine preferences driving vaccine-decision making of different target groups: a systematic review of choice-based experiments.
Diks ME; Hiligsmann M; van der Putten IM
BMC Infect Dis; 2021 Aug; 21(1):879. PubMed ID: 34454441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
